{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:59:47Z","timestamp":1780639187497,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["QKH-zk [2022]030"],"award-info":[{"award-number":["QKH-zk [2022]030"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22167010"],"award-info":[{"award-number":["22167010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360674"],"award-info":[{"award-number":["82360674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmc.2025.118483","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:29:05Z","timestamp":1762597745000},"page":"118483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-NSCLC efficacy of a novel ROR1\/PI3K\u03b1\/BRD4 multi-target inhibitor"],"prefix":"10.1016","volume":"132","author":[{"given":"Ting","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmc.2025.118483_bb0005","first-page":"482","article-title":"Lung cancer: animal model oflung cancer, molecular carcinogenesis oflung cancer, and antitumor effect ofOcimum sanctumagainstlung cancer","volume":"15","author":"Kustiati","year":"2025","journal-title":"Open Vet. J."},{"key":"10.1016\/j.bmc.2025.118483_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106352","article-title":"Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora a\/ PI3K\/ BRD4 inhibition","volume":"132","author":"Fan","year":"2023","journal-title":"Bioorg Chem"},{"issue":"1184","key":"10.1016\/j.bmc.2025.118483_bb0015","first-page":"2025","article-title":"Immunotherapy combined with radiotherapy in the treatment oflung cancer: a meta-analysis of therapeutic effectiveness, safety considerations, and abscopal effect","volume":"25","author":"Gao","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bmc.2025.118483_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10060","article-title":"ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118483_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112940","article-title":"Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells","volume":"409","author":"Nakagawa","year":"2021","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bmc.2025.118483_bb0030","first-page":"2977","article-title":"Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bmc.2025.118483_bb0035","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1038\/s41388-019-0785-7","article-title":"ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma","volume":"38","author":"Yamaguchi","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2025.118483_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13009","article-title":"Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bmc.2025.118483_bb0045","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118483_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/07357907.2019.1651328","article-title":"Synergistic effects of PI3K and c-Myc co-targeting in acute leukemia: shedding new light on resistance to selective PI3K-\u03b4 inhibitor CAL-101","volume":"37","author":"Riyahi","year":"2019","journal-title":"Cancer Investig"},{"key":"10.1016\/j.bmc.2025.118483_bb0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2025.118483_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2014.07.005","article-title":"The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy","volume":"29","author":"Hojjat-Farsangi","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmc.2025.118483_bb0065","article-title":"Tyrosine kinase ROR1 as a target for anti-Cancer therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2025.118483_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1042\/BST20160272","article-title":"Targeting ROR1 identifies new treatment strategies in hematological cancers","volume":"45","author":"Karvonen","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2025.118483_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/164_2021_535","article-title":"Targeting the receptor tyrosine kinase ROR1 by small molecules","volume":"269","author":"Hojjat-Farsangi","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bmc.2025.118483_bb0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jha2.232","article-title":"A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1(+) CLL cells","volume":"2","author":"Ghaderi","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.bmc.2025.118483_bb0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2019.05.016","article-title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer","volume":"458","author":"Liu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2025.118483_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217789","article-title":"Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K\/AKT\/GSK3\u00df activity","volume":"14","author":"Fultang","year":"2019","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.bmc.2025.118483_bb0095","doi-asserted-by":"crossref","first-page":"11046","DOI":"10.3390\/ijms231911046","article-title":"Current molecular combination therapies used for the treatment of breast Cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118483_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41540-023-00292-7","article-title":"Knowledge-based mechanistic modeling accurately predicts disease progression withGefinEGFR-mutant lung adenocarcinoma","volume":"9","author":"L\u2019Hostis","year":"2023","journal-title":"NPJ Syst. Biol. Appl."},{"issue":"1","key":"10.1016\/j.bmc.2025.118483_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/CAD.0000000000001226","article-title":"Severe adverse cutaneousreactionsinduced byGefcombined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report","volume":"33","author":"Shen","year":"2022","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.bmc.2025.118483_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55050","article-title":"GefPlus Chemotherapy vsGefAlone in UntreatedEGFR-Mutant Non\u2013Small Cell Lung Cancer in Patients With Brain Metastases:The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmc.2025.118483_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118011","article-title":"Discovery of 3-(2-aminobenzo[d]thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition","volume":"117","author":"Luo","year":"2025","journal-title":"Bioorganic Med. Chem."},{"issue":"7","key":"10.1016\/j.bmc.2025.118483_bb0120","doi-asserted-by":"crossref","first-page":"2413122","DOI":"10.1002\/advs.202413122","article-title":"BerberinederivativeB68promotestumorimmuneclearanceby dual-targetingBMI1forsenescenceinductionandCSN5for PD-L1degradation","volume":"12","author":"Hu","year":"2025","journal-title":"Adv. Sci."},{"issue":"16","key":"10.1016\/j.bmc.2025.118483_bb0125","doi-asserted-by":"crossref","first-page":"17427","DOI":"10.1021\/acs.jmedchem.5c00974","article-title":"Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors","volume":"68","author":"Baldwin","year":"2025","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:02:25Z","timestamp":1780635745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"alternative-id":["S0968089625004249"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118483","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-NSCLC efficacy of a novel ROR1\/PI3K\u03b1\/BRD4 multi-target inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118483"}}